作者
Scott D Solomon, John JV McMurray, Inder S Anand, Junbo Ge, Carolyn SP Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske, Margaret M Redfield, Jean L Rouleau, Dirk J van Veldhuisen, Faiez Zannad, Michael R Zile, Akshay S Desai, Brian Claggett, Pardeep S Jhund, Sergey A Boytsov, Josep Comin-Colet, John Cleland, Hans-Dirk Düngen, Eva Goncalvesova, Tzvetana Katova, Jose F Kerr Saraiva, Małgorzata Lelonek, Bela Merkely, Michele Senni, Sanjiv J Shah, Jingmin Zhou, Adel R Rizkala, Jianjian Gong, Victor C Shi, Martin P Lefkowitz
发表日期
2019/10/24
期刊
New England Journal of Medicine
卷号
381
期号
17
页码范围
1609-1620
出版商
Massachusetts Medical Society
简介
Background
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor–neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.
Methods
We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril–valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change …
学术搜索中的文章
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam… - New England Journal of Medicine, 2019